QuinoxalineTacrine QT78, a Cholinesterase Inhibitor as a Potential Ligand for Alzheimer’s Disease Therapy

We report the synthesis and relevant pharmacological properties of the quinoxalinetacrine (QT) hybrid QT78 in a project targeted to identify new non-hepatotoxic tacrine derivatives for Alzheimer’s disease therapy. We have found that QT78 is less toxic than tacrine at high concentrations (from 100 μM...

Descripción completa

Detalles Bibliográficos
Autores: Ramos Alonso, Eva, Palomino-Antolín, Alejandra, Bartolini, Manuela, Iriepa, Isabel, Moraleda, Ignacio, Diez-Iriepa, Daniel, Samadi, Abdelouahid, Cortina, Carol V., Chioua, Mourad, Egea, Javier, Romero Martínez, Manuel Alejandro, Marco-Contelles, José
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/12527
Acceso en línea:https://hdl.handle.net/20.500.14352/12527
Access Level:acceso abierto
Palabra clave:Alzheimer’s disease
cholinesterase inhibitor
hepatotoxicity
molecular modeling
neuroprotection
quinoxalines
quinoxalinetacrines
tacrine
Neurociencias (Medicina)
Farmacología veterinaria
2490 Neurociencias
3109.08 Farmacología
Descripción
Sumario:We report the synthesis and relevant pharmacological properties of the quinoxalinetacrine (QT) hybrid QT78 in a project targeted to identify new non-hepatotoxic tacrine derivatives for Alzheimer’s disease therapy. We have found that QT78 is less toxic than tacrine at high concentrations (from 100 μM to 1 mM), less potent than tacrine as a ChE inhibitor, but shows selective BuChE inhibition (IC50 (hAChE) = 22.0 ± 1.3 μM; IC50 (hBuChE) = 6.79 ± 0.33 μM). Moreover, QT78 showed effective and strong neuroprotection against diverse toxic stimuli, such as rotenone plus oligomycin-A or okadaic acid, of biological significance for Alzheimer’s disease.